Financial intelligence for Asia's healthcare markets
 
 
Remember me:

Australia: ResApp plans new cough trial

Shares in ResApp Health jumped more than 28% earlier this week after the investigators of the group’s clinical trial confirmed that their study was not an accurate or reliable evaluation of ResApp’s algorithms. The release of the initial trials caused shares in the Perth-based digital healthcare operator that focuses on respiratory diseases to crash 77% after they showed significant problems with its main product.

“Having completed a review with all relevant parties it is clear that the first US study was not a reliable evaluation of ResApp’s algorithms and that the top line results do not reflect the actual performance of ResApp’s technology,” said ResApp CEO and managing director Tony Keating.

ResApp’s main product is a cough-based diagnostic test that works with a smartphone to analyse the sound of a patient’s cough and to diagnose any underlying conditions.

In that trial, two main problems were found. First, that contrary to instructions and training, a high number of patients were treated before clinical research staff recorded their cough sounds. And second, a high number of recordings were found to contain a second person’s cough sounds or an unacceptable amount of background noise and interference.

ResApp  plans to restart the study  this winter in the US.

To improve the data gathering element of the study, ResApp will be present onsite conducting clinical study team training, reviewing enrolment procedures and verifying data to help ensure that high-quality cough sounds are collected as early as possible during the patient’s hospital visit and prior to any treatment known to affect cough analysis. Every cough sound collected will be quality checked within days of its recording to ensure that all of the data used to subsequently analyse the performance of the algorithm is uncorrupted and high fidelity. An improved audio recording smartphone application incorporating built-in checklists, automated background noise estimation and additional visual aids will be deployed further to support the data collection teams and eliminate inappropriate collection of cough data with background noise contamination.

ResApp’s algorithms have also been modified to reduce the impact of the low frequency electronic interference found in nearly 15% of the previous study recordings.

ResApp plans to broaden its paediatric clinical strategy by reconfiguring its Australian study to support European and Australian regulatory filings directly. Since earlier this year, the Australian paediatric study at Joondalup Hospital has been recruiting patients for double-blind prospective analysis with 230 patients recruited to date. To support regulatory submissions, a team of clinicians will perform adjudication and Curtin University health researchers will provide independent statistical analysis.

ResApp shares closed on Monday at A$0.09 (US$0.07).

Posted on: 06/09/2017 UTC+08:00


News

Metro Pacific Hospital Holdings, the healthcare unit of industrial conglomerate Metro Pacific Investments, is finally expected to push the button on its Philippine Stock Exchange IPO next year.
MedAdvisor will form a 50:50 joint venture based in Singapore with Zuellig Pharma to commercialise MedAdvisor’s medication management platform in Asia.
Thermo Fisher Scientific, the world leader in serving science, today opened its first Bioprocess Design Centre in Shanghai, China. The new centre is part of a strategy to establish a centre of excellence where Thermo Fisher scientists can connect and collaborate with biologic developers to design optimal bioprocessing solutions.
Mitsui & Co will acquire an additional 16% of the shares of one of Asia’s largest private hospital groups, IHH Healthcare, from Malaysia’s Khazanah Nasional.
Mach7 Technologies, a company specialising in innovative data management solutions for healthcare providers, has raised A$3 million (US$2.2 million) via a private placement.
Pacific Edge is to raise NZ$12 million (US$8.2 million) in a share placement and via a share purchase plan.
We Doctor Holdings, China's leading technology-enabled medical and healthcare solutions platform, joined hands today in Guangzhou with the Guangdong Women and Children's Hospital and Health Institute to launch China's first provincial-level internet hospital for women and children.
Singapore-based medtech startup Ark has raised US$40 million in Series A funding round led by Venturecraft shareholders and joined by Gaorong Capital – formerly known as Banyan Capital. It is one of the largest Series A rounds closed by a southeast Asian firm.



Analysis

French-based international ophthalmic optics company Essilor has signed Letters of Intent with the Royal Government of Bhutan and the Central Monastic Body to strengthen the country’s vision care infrastructure.
April Chang, country manager at Cigna Singapore, argues that wellness programmes at work can lead to reduced absenteeism, higher productivity and increased morale among employees.
Steven Fang understands how to set up a healthcare company. Not only is he chief executive and founder of ASX-listed oncology company Invitrocue, he was also the founder of Singapore-based Cordlife Group, a healthcare company which provides cord blood and cord lining banking services.
Imagine a world in which you can consult with your doctor via video. She asks for a blood sample, which can be collected and analysed from a device in your home. After that is diagnosed, the prescription is automatically sent to the pharmacy and Uber then picks it up. The time from diagnosis to drugs at your home is only 60 minutes.
The digitisation of health data through blockchain technology is a groundbreaking solution that will empower patients and provide them with better access to healthcare.
For too many companies, a stock market flotation is the be all and end all. Chief executives have spent months on roadshows, locked up with bankers and lawyers. Understandably they think that they can now rest on their laurels.
Today is the launch of Asia Pacific’s first Life Sciences Centre of Excellence. It is part of global management consulting firm LEK Consulting’s Healthcare Insights Centre and aims to drive thought leadership and innovation to elevate the life sciences ecosystem in Singapore and the region.
Dementia remains one of the biggest chronic medical issues to face families. A determination to treat the illness is a challenge that Charles Stacey, president and CEO of Singapore-based Cerecin, has grasped with both hands.
my images

Podcasts

HealthInvestor Asia twitter feed